PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

Final random-forest-based models outperformed all publicly available risk scores on internal and external test sets.

MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.

Head and neck cancers represent a biologically heterogeneous group of malignancies requiring accurate diagnosis, staging, and risk stratification for ...

Caris POA members advance precision medicine through collaborative research aimed at improving clinical outcomes for cancer ...

A skin cancer diagnosis can seem to arrive out of nowhere. But buried in years of health records, prescription histories, and ...

WHAT: Researchers from the Johns Hopkins Kimmel Cancer Center will present new research findings and receive honors and ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

Researchers at the University of Sussex, in collaboration with scientists from different institutes worldwide, have ...

A nanophotonic biochip combined with AI detects microRNA biomarkers in 20 minutes with high accuracy, enabling rapid, ...